/ORYZF
ORYZF Stock - Oryzon Genomics S.A.
Healthcare|BiotechnologyOTC
$3.36+0.00%
+$0.00 (+0.00%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.47
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.70
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ORYZF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.33 – $3.39
TARGET (TP)$3.86
STOP LOSS$3.09
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.49
52W High$4.38
52W Low$1.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.36M | $14.19M | $15.70M | $10.62M | $9.52M |
| Gross Profit | $7.06M | $13.95M | $15.23M | $9.87M | $8.99M |
| Gross Margin | 95.9% | 98.3% | 97.0% | 93.0% | 94.5% |
| Operating Income | $-4,422,963 | $-4,549,193 | $-5,489,910 | $-7,010,565 | $-4,294,223 |
| Net Income | $-3,665,417 | $-3,352,943 | $-4,231,403 | $-4,686,970 | $-3,399,557 |
| Net Margin | -49.8% | -23.6% | -27.0% | -44.2% | -35.7% |
| EPS | $-0.06 | $-0.06 | $-0.08 | $-0.09 | $-0.06 |
Company Overview
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ORYZFBeat Rate
67%
Last 18 quarters
Avg Surprise
+47.6%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$0.01
Q4 2025
EPS Surprise History
Q3 23
+53.9%
$-0.02vs$-0.04
Q1 24
+45.4%
$-0.03vs$-0.06
Q2 24
+32.6%
$-0.02vs$-0.03
Q3 24
+118.3%
$0.00vs$-0.01
Q4 24
-17.2%
$-0.02vs$-0.02
Q1 25
+22.3%
$-0.02vs$-0.03
Q2 25
+0.2%
$-0.03vs$-0.03
Q4 25
+161.3%
$0.01vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.01 | $0.01 | +161.3% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.03 | $-0.03 | +0.2% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.03 | $-0.02 | +22.3% | ✓ BEAT |
Q4 2024 | Oct 24, 2024 | $-0.02 | $-0.02 | -17.2% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $-0.01 | $0.00 | +118.3% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.03 | $-0.02 | +32.6% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.06 | $-0.03 | +45.4% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $-0.04 | $-0.02 | +53.9% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.03 | $0.02 | +166.6% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.03 | $-0.03 | -3.5% | ✗ MISS |
Q1 2023 | Feb 17, 2023 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.05 | $-0.01 | +80.0% | ✓ BEAT |
Q3 2022 | Jul 22, 2022 | $0.00 | $0.01 | +130.4% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.02 | $-0.03 | -31.8% | ✗ MISS |
Q1 2022 | Feb 7, 2022 | $-0.04 | $-0.04 | -2.4% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-0.02 | $-0.02 | -3.8% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $0.01 | $0.02 | +166.7% | ✓ BEAT |
Q2 2021 | May 7, 2021 | $-0.02 | $-0.04 | -81.8% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ORYZF
What is ORYZF's current stock price?
Oryzon Genomics S.A. (ORYZF) is currently trading at $3.36 per share. The stock has moved +0.00% today.
What is the analyst price target for ORYZF?
No analyst price targets are currently available for this stock.
What sector is Oryzon Genomics S.A. in?
Oryzon Genomics S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ORYZF's market cap?
Oryzon Genomics S.A. has a market capitalization of $0.26 billion, making it a small-cap company.
Does ORYZF pay dividends?
No, Oryzon Genomics S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorEVGRF
China Evergrande New Energy Vehicle Group Limited
$0.00
Mkt Cap: $0.0B
GNFTF
Genfit S.A.
$4.14
Mkt Cap: $0.2B
HNSBF
Hansa Biopharma AB (publ)
$2.91
Mkt Cap: $0.2B
JWCTF
JW (Cayman) Therapeutics Co. Ltd
$0.39
Mkt Cap: $0.2B
NGENF
NervGen Pharma Corp.
$4.52
Mkt Cap: $0.4B
OPORF
hVIVO plc
$0.24
Mkt Cap: $0.2B
ORPEF
Orpea S.A.
$14.22
Mkt Cap: $2.3B
SLNCF
Silence Therapeutics plc
$2.03
Mkt Cap: $0.3B
SPHDF
Santhera Pharmaceuticals Holding AG
$13.35
Mkt Cap: $0.2B
TRGNF
Transgene S.A.
$1.00
Mkt Cap: $0.1B
Explore stocks similar to ORYZF for comparison